 |
|
|
| |
Evaluation of the efficacy and tolerability
of JNJ-4178 (AL-335, odalasvir, and simeprevir) in hepatitis C virus-infected patients without cirrhosis: The Phase IIb OMEGA-1 study
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting 2017; Washington, DC, USA; October 20-24, 2017.
Stefan Zeuzem,1 Stefan Bourgeois,2 Susan Greenbloom,3 Maria Buti,4
Alessio Aghemo,5 Ewa Janczewska,6 Seng Gee Lim,7 Chris Corbett,8
Wouter Willems,8 Leen Vijgen,8 Sivi Ouwerkerk-Mahadevan,8
Maria Beumont,8 Rekha Sinha,9 Ronald Kalmeijer,9 Michael Biermer8
1JW Goethe University, Frankfurt am Main, Germany; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Toronto Digestive Disease Associates, Inc., Vaughan, ON, Canada; 4Hospital Vall d'Hebron and Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain; 5Humanitas University, Rozzano, Italy; 6Outpatients Clinic for Hepatology, ID Clinic, Myslowice, Poland; 7National University Hospital, Singapore; 8Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium;
9Janssen Research & Development, LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
